Uses of chitosan for treating different forms of serious obstetrics hemorrhages

Carles, Gabriel; Dabiri, Clément; Mchirgui, Ali; Saoudi, El Oula; Hcini, Najeh; Pouget, K.; Seve, Beatrice; Matteis, Bruno de

doi:10.1016/j.jogoh.2017.08.003

Cited by 19 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Human clinical trials utilizing commercially available and custom-made chitin and chitosan wound treatments, resulting in significant improvements in the healing of ear, nasal, oral, and skin wounds, in addition to treatment of ulcers and serious hemorrhages. Data from [162][163][164][165][166][167][168][169][170][171][172][173][174][175][176][177]. Chitosan, unknown [177] These wound treatments have experienced significant success in oral clinical trials where they have been used to treat aphthous stomatitis (mouth ulcers), postoperative and tooth extraction wounds.…”

Section: Human Clinical Trials Utilizing Chitin and Chitosan For Wounmentioning

confidence: 99%

Crab vs. Mushroom: A Review of Crustacean and Fungal Chitin in Wound Treatment

et al. 2020

View full text Add to dashboard Cite

Chitin and its derivative chitosan are popular constituents in wound-treatment technologies due to their nanoscale fibrous morphology and attractive biomedical properties that accelerate healing and reduce scarring. These abundant natural polymers found in arthropod exoskeletons and fungal cell walls affect almost every phase of the healing process, acting as hemostatic and antibacterial agents that also support cell proliferation and attachment. However, key differences exist in the structure, properties, processing, and associated polymers of fungal and arthropod chitin, affecting their respective application to wound treatment. High purity crustacean-derived chitin and chitosan have been widely investigated for wound-treatment applications, with research incorporating chemically modified chitosan derivatives and advanced nanocomposite dressings utilizing biocompatible additives, such as natural polysaccharides, mineral clays, and metal nanoparticles used to achieve excellent mechanical and biomedical properties. Conversely, fungi-derived chitin is covalently decorated with -glucan and has received less research interest despite its mass production potential, simple extraction process, variations in chitin and associated polymer content, and the established healing properties of fungal exopolysaccharides. This review investigates the proven biomedical properties of both fungal- and crustacean-derived chitin and chitosan, their healing mechanisms, and their potential to advance modern wound-treatment methods through further research and practical application.

show abstract

Section: Human Clinical Trials Utilizing Chitin and Chitosan For Wounmentioning

confidence: 99%

Crab vs. Mushroom: A Review of Crustacean and Fungal Chitin in Wound Treatment

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In recent papers, surgical treatment of LUSA was described by means of different methods like: curettage, embolisation, vaginal packing, bilateral cervix apex clamping, transvaginal cervicouterine artery ligation, double balloon tamponade, obstruction of vascularisation by means of uterine traction towards vagina, "holding the cervix" technique, " shing for the balloon shaft" and perpendicular compressive cervical stitches and nally hysterectomy [6,9,[10][11][12][13][14][15][16][17][18][19][20][21][22][23]. Panda et al [6] in 2009. published very appreciable paper about clinical entity known as primary LUSA that should be clearly distinguished from corporeal uterine atony.…”

Section: Discussionmentioning

confidence: 99%

“…In the total number of 13 359 vaginal deliveries, BCAC was performed in 44 cases (0,33%) with e cacy of 93,2%. Recent studies have shown good hemostasis accomplishment in the treatment of LUSA with the use of Chitosan gauze [12,22]. Dueckelmann and coworkers [12] have presented results of their comparative study in the treatment of women with PPH with either uterine packing with chitosan covered gauze compared to balloon tamponade.…”

Section: Discussionmentioning

confidence: 99%

Surgical Treatment of Early Postpartum Hemorrhage Caused by Lower Uterine Segment Atony

Habek¹,

Márton

Prka

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose: Lower uterine segment atony is recently being recognized as one of the major reasons for early postpartum hemorrhage.Methods: We present our experience in surgical treatment of lower uterine segment atony patients that were delivered in our tertiary perinatal center during the 10 years period (2010-2019).Results: This particular study enrolled total number of 29 543 deliveries with 215 cases of early PPH (0,72%). LUSA was diagnosed in 44 cases or in 29,93% in all uterine atony cases. Exploration of the lower uterine segment accompanied by evacuation of the coagula was conducted in 5 cases (11,36%), haemostatic ligation procedures according to authors: Losickaja in 2 cases, Hebisch-Huch in 9 cases, Habek in 5 cases, Hebisch-Huch+Losickaja in 9 cases. Evacuation procedures were combined with ligation techniques in 7 cases, evacuation methods with ligation techniques and balloon tamponade in 2 cases, exploration combined with gauze tamponade in 1 case and ligation procedures with balloon tamponade in 3 cases. According to our results, haemostatic ligation procedures alone or combined with tamponade, have shown to be highly effective in 88,63%. Conclusion: Transvaginal approach for surgical treatment of lower uterine segment atony is accessible, feasible, successful and life saving. It can be easily performed in inpatient and outpatient care settings followed by administration of uterotonics, uterostiptics and tranexamic acid and fluid replacement. All of the above mentioned methods are of great importance in the prevention and treatment of obstetric hemorrhagic shock, development of coagulopathy, multiorgan failure, postpartum hysterectomy and finally vital for fertility preservation.

show abstract

“…We previously reported our experience in successfully using Chitosan, a potent hemostatic agent derived from chitin, to treat severe obstetric bleeding induced by uterine atony, multiple vaginal tears, and bleeding after hemostatic hysterectomy [7]. Since 2015, we have been regularly continuing to use Chitosan to manage gynecological or obstetrical hemorrhage.…”

Section: Introductionmentioning

confidence: 99%